Designing a Predictive Tool to Identify Whether a Cancer Patient Has Bacteremia Due to Ceftriaxone-Resistant Escherichia Coli

Last updated: April 28, 2021
Sponsor: M.D. Anderson Cancer Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neoplasms

Soft Tissue Infections

Sepsis And Septicemia

Treatment

N/A

Clinical Study ID

NCT04866186
2020-1000
NCI-2021-02019
2020-1000
  • Ages > 18
  • All Genders

Study Summary

This study aims to develop a tool to predict whether a cancer patient has bacteria in the blood (bacteremia) due to ceftriaxone-resistant Escherichia (E.) coli. This study may help researchers identify risk factors for ceftriaxone-resistant E. coli bacteremia in cancer patients and improve antibiotic treatment in these patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age >= 18 years
  • Documented clinical bloodstream infection (BSI) due to E. coli determined by confirmedculture

Exclusion

Exclusion Criteria:

  • Patients < 18 years of age

Study Design

Total Participants: 570
Study Start date:
December 15, 2020
Estimated Completion Date:
July 01, 2021

Study Description

PRIMARY OBJECTIVES:

I. Develop a decision tree to predict whether an E. coli bacteremic patient is infected with ceftriaxone-resistant E. coli.

II. Develop a traditional risk factor scoring system to predict whether an E. coli bacteremic patient is infected with ceftriaxone-resistant E. coli.

III. Compare the predictive accuracy of decision tree approach to traditional risk factor scoring system.

OUTLINE:

Patients' electronic health records are reviewed retrospectively.

Connect with a study center

  • M D Anderson Cancer Center

    Houston, Texas 77030
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.